Table 1 Top 10 upregulated (top) and top 10 downregulated (bottom) L1000 genes with expression levels from mechanism of action networks in Fig. 4

From: Drug and disease signature integration identifies synergistic combinations in glioblastoma

BET

mTOR/PI3K

CDK

HDAC

HSP90

MEK

PNKP

9.29

NPDC1

9.69

PAK1

11.67

PRCP

10.4

SMNDC1

10.75

HSPB1

10

SLC25A4

9

MAP2K5

9.88

CAMSAP2

11.78

MNAT1

10.6

SPAG7

11.25

HMOX1

8.33

CPNE3

9.14

FOXO4

9.44

TBXA2R

11.89

PTPN1

10.4

NUDT9

11.5

ECH1

7.5

STUB1

8.71

MBTPS1

9.63

MAPK9

12.56

FOXO4

10.4

HSPD1

11.75

TSC22D3

7.17

AKR7A2

9.14

HSD17B11

9.38

TCEA2

12.56

TCEA2

10.4

SNX6

11

NFIL3

9.17

BNIP3L

8.57

CBLB

9.38

SOCS2

11.56

IER3

11.2

HSPA8

12

PIK3R3

7.17

STXBP1

10.29

CDK19

9.75

NFKBIE

12

RRAGA

9.8

KIAA0494

12

PPIC

7.83

CIRBP

8.14

SNCA

11.19

ADAT1

12.11

LIPA

10.8

ATP2C1

12

NNT

8

TMEM2

8.29

KLHDC2

11.25

RAB27A

11.89

ANO10

10

PRUNE

11.75

NFKBIA

7.17

LRPAP1

8.29

POLD4

11.06

GPC1

12.89

SSBP2

9.8

ARID4B

11

BRP44

8.17

DECR1

−7.29

CYCS

−11.38

COPB2

−10.89

PUF60

−11.8

SLC37A4

−11.75

STX1A

−9.83

ATF1

−6.86

GTF2A2

−11.38

CDC25B

−11.11

SUV39H1

−13.4

TSEN2

−10.75

DUSP6

−10.67

TMEM109

−8

BIRC5

−10.06

KIAA0528

−12

ADI1

−13

CETN3

−10.75

DUSP4

−8.83

CRYZ

−7

ICMT

−9.94

PCM1

−11.33

TIMELESS

−11.6

TIPARP

−11.25

EGR1

−10.67

IKBKE

−7

MYBL2

−9.88

ATF1

−11.67

PFKL

−11.6

NUP88

−11.75

CCND1

−8.83

ICAM3

−7.86

PGAM1

−10.69

CASC3

−11.67

MICALL1

−11.6

PXMP2

−11.25

SPRED2

−8.33

PYCR1

−9.86

MYCBP

−10.19

SCAND1

−11

NUP85

−11.8

IER3

−11

FOSL1

−9.5

SORBS3

−8

PHGDH

−10.13

ADAM10

−12.22

AKAP8

−11.6

PAFAH1B3

−12

ITGB5

−10.33

PSMB8

−7.43

RUVBL1

−9.88

CLTC

−11.78

DCTD

−11.6

CCDC85B

−13.25

MAT2A

−7.17

PLOD3

−8.86

POP4

−11.13

ATMIN

−11.56

KEAP1

−13.4

AMDHD2

−12.25

HMGA2

−8.5